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Abstract
Background: Accurate detection and analysis of circulating tumor cells plays an important role in the diagnosis and
treatment of metastatic cancer treatment.
Methods and Findings: A cell microarray chip was used to detect spiked carcinoma cells among leukocytes. The chip, with
20,944 microchambers (105 mm width and 50 mm depth), was made from polystyrene; and the formation of monolayers of
leukocytes in the microchambers was observed. Cultured human T lymphoblastoid leukemia (CCRF-CEM) cells were used to
examine the potential of the cell microarray chip for the detection of spiked carcinoma cells. A T lymphoblastoid leukemia
suspension was dispersed on the chip surface, followed by 15 min standing to allow the leukocytes to settle down into the
microchambers. Approximately 29 leukocytes were found in each microchamber when about 600,000 leukocytes in total
were dispersed onto a cell microarray chip. Similarly, when leukocytes isolated from human whole blood were used,
approximately 89 leukocytes entered each microchamber when about 1,800,000 leukocytes in total were placed onto the
cell microarray chip. After washing the chip surface, PE-labeled anti-cytokeratin monoclonal antibody and APC-labeled anti-
CD326 (EpCAM) monoclonal antibody solution were dispersed onto the chip surface and allowed to react for 15 min; and
then a microarray scanner was employed to detect any fluorescence-positive cells within 20 min. In the experiments using
spiked carcinoma cells (NCI-H1650, 0.01 to 0.0001%), accurate detection of carcinoma cells was achieved with PE-labeled
anti-cytokeratin monoclonal antibody. Furthermore, verification of carcinoma cells in the microchambers was performed by
double staining with the above monoclonal antibodies.
Conclusion: The potential application of the cell microarray chip for the detection of CTCs was shown, thus demonstrating
accurate detection by double staining for cytokeratin and EpCAM at the single carcinoma cell level.
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Introduction
Circulating tumor cells (CTCs) are known as the cells that have
detached from a primary tumor and are circulating in the
bloodstream, and the invasion of other tissues by them may occur
very early during tumor development [1]. The presence of CTCs
in the bloodstream supports the ‘‘seed and soil’’ theory of
metastasis formation [2]. Although CTCs are as few as 1 cell
per 10
9 hematologic cells in the blood [3], these cells were shown
to play an important role in the metastatic spread of cancer [4].
Thus the detection of CTCs would be expected to provide a
powerful tool for cancer prognosis, diagnosis of minimal residual
disease, assessment of tumor sensitivity to cancer drugs, and
personalization of anticancer therapy [5]. Furthermore, highly
sensitive and specific identification of CTCs could be useful for the
early diagnosis of invasive cancers [2]. The CellSearch System
TM
(Veridex
TM, Raritan, NJ), which is based on immunomagnetic cell
selection and enrichment by use of ferrofluid nanoparticles coated
with anti-EpCAM (epithelial cell adhesion molecule, CD326)
antibodies and the use of anti-CD45 antibody to discriminate
leukocytes, is the only US Food and Drug Administration (FDA)-
approved CTC diagnosis system on the market. The enriched
population is stained with anti-cytokeratin antibody to discrimi-
nate between epithelial cells and contaminating leukocytes.
Recently, a microfluidic platform capable of efficient and selective
separation of CTCs from peripheral whole blood by using the
interaction of CTCs with antibody-coated microposts was
developed [3].
Microchip technologies have been expected to allow high-
throughput and highly sensitive analysis of the function of
individual cells [6]. In a previous study of ours, we developed a
single-cell microarray chip for the analysis of antigen-specific
single B-cells [7]. Furthermore, thereafter we developed a high-
throughput screening and analysis system for the detection of
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ity and short time of operation and involving a cell microarray
chip made from polystyrene with over 20,000 individually
addressable microchambers [8]. Presently we employed this cell
microarray chip system for the detection of human lung
adenocarcinoma cells among leukocytes by staining with
antibodies specific for epithelial cells or tumor cells. Our cell
microarray chip was improved to allow the regular dispersion of
hematologic cells and carcinoma cells to form a monolayer in the
microchambers; and analysis of the cells following incubation
with protein-staining fluorescent dyes was then carried out by
use of a microarray scanner for the detection of the presence of
fluorescence-positive carcinoma cells among the leukocytes
(Fig. 1). In this study, we showed the potential of our cell
microarray chip system for the accurate detection of carcinoma
cells among leukocytes in a short time.
Figure 1. Schematic process for detection of CTCs on a cell microarray chip. (A) Human leukocytes/carcinoma cells are dispersed on a cell
microarray chip, followed by 15 minutes’ standing to allow the cells to settle down into the microchambers, and are then stained with fluorescence-
labeled antibodies against carcinoma cells. (B) Fluorescence-positive CTCs are detected by using a microarray scanner with a confocal fluorescence
laser. (C) The target CTCs are analyzed quantitatively at the single-cell level.
doi:10.1371/journal.pone.0032370.g001
Figure 2. Construction of a cell microarray chip. (A) Photo of an actual cell microarray chip. (B, C) SEM images of a cell microarray chip. The cell
microarray chip comprises 20,944 microchambers in a plastic slide on a glass slide. The cell microarray chip has 112 (1468) clusters, each having 187
microchambers. (D) Each microchamber is 105 mm in upper diameter, 50 mm in depth, and has the shape of a frustum with a 68-mm diameter flat
bottom for the accommodation of leukocytes as a monolayer.
doi:10.1371/journal.pone.0032370.g002
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Construction of a cell microarray chip
As shown in Fig. 2, the cell microarray chip comprised 20,944
microchambers (105-mm upper diameter, 68-mm lower diameter,
50-mm depth, and spacing as indicated) and was made from
polystyrene by the Lithographic Galvanoformung Abformung
process by Starlight Co. Ltd. (Osaka, Japan) [8]. Each micro-
chamber thus had the shape of a frustum. The polystyrene
microarray chip was fabricated by injection molding with a nickel
mold. The microarray chip contained 112 (1468) clusters, each
having 187 microchambers and a block number for easy
confirmation of the presence of epithelial cells. The cell microarray
chip surface was rendered hydrophilic by means of reactive ion-
etching treatment by use of a SAMCO RIE system (SAMCO,
Inc., Tokyo, Japan) to achieve cell confinement in the micro-
chambers. The effect of reactive ion-etching exposure on the
microarray chip surface was examined by measuring the contact
angle of water on the chip surface by using a contact-angle meter
(Kyowa Interface Science Co., Ltd., Saitama, Japan) [7,8].
Cell cultures and preparation for analysis on a cell
microarray chip
Human bronchioalveolar carcinoma cells (NCI-H1650) were
cultured in RPMI 1640 (Nakalai Tesque, Kyoto, Japan)
containing 10% fetal bovine serum and antibiotics (100 U/ml
penicillin-streptomycin ([GIBCO, Life Technologies Co., CA])
and 250 ng/ml Fungizone (GIBCO), and subsequently harvested
by using trypsin. Human T lymphoblastoid leukemia cells (CCRF-
CEM) were also cultured in a similar medium, and harvested by
centrifugation. Cell suspensions of 7.5610
4, 7.5610
3, and 7.5610
2
NCI-H1650 cells/ml of medium were prepared, and 10 ml of each
of these cell suspensions was added to 1.0 ml of 7.5610
6 CCRF-
CEM cells/ml to give 0.01,0.0001% NCI-H1650 samples,
respectively. Five-hundred microliters of the respective cell
samples were employed for the analysis on a cell microarray chip
to detect the carcinoma cells.
For the preparation of carcinoma cell-spiked blood samples,
200 ml of 2.5610
2 cells/ml or 2.5610
3 NCI-H1650 cells were
added to 10 ml of whole human blood (50 or 500 carcinoma cells
spiked). For isolation of the carcinoma cells and leukocytes from
the blood samples, 10 ml of the spiked whole blood was layered
onto 10 ml of Polymorphprep
TM (AXIS-SHIELD PoC AS, Oslo,
Norway), and then centrifuged at 5006g, for 30 min at room
temperature. By use of a Pasteur pipette, the leukocyte/carcinoma
cell fraction was carefully harvested, washed with RPMI 1640
medium, and suspended in 2 ml of RPMI 1640 medium. The
numbers of leukocytes were counted by use of a hemocytometer
prior to the dispersion on a cell microarray chip. For the analysis
on a cell microarray chip to detect carcinoma cells, 500-ml samples
of the isolated leukocytes/carcinoma cells were employed as
described below. For the double staining of cytokeratin and
EpCAM, 200 ml of 12.5610
4 NCI-H1650 cells/ml were added to
1.0 ml of 7.5610
6 CCRF-CEM cells/ml or 10 ml of whole blood
(2.5610
4 cells spiked) for the preparation of carcinoma cell-spiked
blood samples.
Detection of carcinoma cells on a cell microarray chip
For assessment of tight monolayers of the cultured cells in the
microchambers, we examined leukocytes and carcinoma cells
separately. First, 500 ml of 2.5610
6, 5.0610
6, 7.5610
6 or 1.0610
7
T lymphoblastoid leukemia/ml of RPM1 1640 medium was
dispersed on a cell microarray chip, followed by 15 minutes’
standing to allow the cells to settle down into the microchambers
under gravitational force. For confirmation of tight monolayers of
the carcinoma cells in the microchambers, 500 ml of 7.5610
6
carcinoma cells/ml of RPM1 1640 was dispersed on a microarray
chip, followed by 15 minutes’ standing. Then, excess cells on the
Figure 3. Dispersion of T lymphoblastoid leukemia cells on a cell microarray chip and confinement in the microchambers. (A, B)
Photographic light microscopic images of T lymphoblastoid leukemia cells incubated on a cell microarray chip before (A) and after (B) washing of the
chip surface. (C–F) Photos of microchamber appearance after washing when T lymphoblastoid leukemia suspensions of 2.5610
6 (C), 5.0610
6 (D),
7.5610
6(E) or 1.0610
7 (F) cells/ml were applied to the microarray chip. Concentrations of 7.5610
6 cells/ml of T lymphoblastoid leukemia and above
afforded tight confinement and formation of a monolayer in the microchambers. (Bar: 20 mm).
doi:10.1371/journal.pone.0032370.g003
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medium, and the microchambers were examined by light
microscopy.
For the analysis of carcinoma cell-spiked blood samples, 500 ml
of leukocytes/carcinoma cells isolated with Polymorphprep
TM
were dispersed onto a cell microarray chip, and confinement of the
cells as monolayers in the microchambers was performed as
described above.
For the staining of cytokeratin in the dispersed cells in the
microchambers, 500 ml of PE-labeled anti-cytokeratin monoclonal
antibody (BD Biosciences, CA) solution (1: 50 dilution in 0.05%
Triton X-100/PBS), which is specific for cytokeratins 7 and 8 (Ex:
543 nm, Em: 573 nm), was dispersed onto the cell microarray
chip and allowed to react for 15 min; and then the chip surface
were washed with RPMI 1640 medium. For the double staining of
cytokeratin and EpCAM, the cell staining solution was prepared
by adding 20 ml of PE-labeled anti-cytokeratin monoclonal
antibody solution and 20 ml of APC-labeled anti-EpCAM
monoclonal antibody (Biolegend, CA, Ex: 633 nm, Em: 660 nm)
solution to 1 ml of 0.05% Triton X-100/PBS. Then 500 ml of this
solution was dispersed onto the cell microarray chip and permitted
to react for 15 min, and then the chip surface was washed with
RPMI 1640 medium. For the staining of CD45, which is antigen
present on all human leukocytes, 500 ml of APC-labeled anti-CD
45 monoclonal antibody (BD Bioscience, Ex: 633 nm, Em:
660 nm) solution (1: 200 dilution in 0.05% Triton X-100/PBS)
was dispersed onto the cell microarray chip and allowed to react
for 15 min; and then the chip surface was washed with RPMI
1640 medium. For the staining of cell membranes, the cells in each
microchamber were incubated for 15 min with 500 ml of DiD
(Invitrogen, Life Technologies Co., CA, Ex: 644 nm, Em:
665 nm) solution (1: 1000 dilution in 0.05% Triton X-100/
PBS), and then the chip surface was washed with RPMI 1640
medium.
Each cell microarray chip was scanned for 20 min with a
confocal laser-based fluorescence microarray scanner, CRBIO IIe
(Hitachi Software Engineering Co., Ltd., Tokyo, Japan). This
system exhibits a resolution of 10 mm and a sensitivity of ,0.1
fluorescent molecule/mm
2, and is fitted with filters with emission
wavelengths of 532 and 635 nm. The fluorescence intensity of
spots with a 15-mm diameter, nearly corresponding to individual
carcinoma cells, was determined with DNASIS Array version 2.1
software (Hitachi Software Engineering Co., Ltd.), and the spots
that exhibited fluorescence intensity that was 10 times above that
of unstained cells were taken to be positive ones in antibody
staining. For scatter-plot analysis of carcinoma cell-spiked blood
samples, 12 spots with a 15-mm diameter in the each micro-
chamber in 3 cluster areas representing 561 microchambers (total
of 6732 spots) were examined.
Statistical analysis
The number of fluorescence-positive cells was determined for
each cell sample. Data were expressed as the mean 6 standard
error (SE) of at least 3 different experiments.
Ethics
This study was approved by the Institutional Review Board of
the National Institute of Advanced Industrial Science and
Technology regarding the use of human derivatives for biomedical
research, and by the Ethics Committee of University of
Tokushima. All subjects provided written informed consent for
the collection of samples and subsequent analysis.
Results
Dispersion of carcinoma cells and leukocytes on a cell
microarray chip
To achieve the confinement of carcinoma cells and leukocytes
in the microchambers, we optimized the hydrophilicity of the
microarray chip surface by means of reactive ion-etching
exposure [7,8]. Eighty-second exposure gave appropriate hydro-
philicity to the chip surface, and the cells could settle into each
microchamber (data not shown). For the formation of a
monolayer of cells on the bottom surface of the microchambers
after washing, the cell microarray chip was designed to have
microchambers with a 105-mm upper diameter, 50-mmd e p t h ,
and a frustum shape (Fig. 2). The suspension of T lymphoblastoid
leukemia was dropped onto the chip by using a pipette, and then
the leukocytes settled down under gravitational force and adhered
to the chip surface as multilayers (Fig. 3A). After the chip surface
had been washed with medium by use of a pipette, only those
leukocytes that had adhered to the bottom surface of each
microchamber as a monolayer remained (Fig. 3B–F). We
observed that the number of leukocytes confined to the
microchambers depended on the concentration of leukocytes
introduced onto the cell microarray chip, and leukocytes were
tightly confined when a concentration of 7.5610
6 cells/ml of cell
suspension or higher was used (Fig. 3E, F). The number of
confined leukocytes was determined to be 2962 (mean 6
standard error (SE)) per microchamber (n=40) with 7.5610
6
cells/ml of cell suspension (Fig. 3E). So, over 600,000 leukocytes
were dispersed as a monolayer in the microchambers on a cell
microarray chip when the cell suspension of 7.5610
6 cells/ml was
used. A similar dispersion of bronchioalveolar carcinoma cells as
Figure 4. Dispersion of carcinoma cells on a cell microarray chip and confinement in the microchambers. (A, B) Photographic light
microscopic images of carcinoma cells on a cell microarray chip before (A) and after (B) washing of the chip surface. (C) Carcinoma cells showed tight
confinement and had formed a monolayer in the microchamber when a concentration of 7.5610
6 cells/ml was used. (Bar: 20 mm).
doi:10.1371/journal.pone.0032370.g004
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suspension of 7.5610
6 cells/ml (Fig. 4). Similarly, for leukocytes
isolated from whole blood, monolayer formation in the micro-
chambers was confirmed (Fig. 5). The number of confined
leukocytes was determined to be 8964 (mean 6 SE) per
microchamber (n=40); i.e., about 1,800,000 leukocytes were
dispersed as a monolayer in the microchambers on a cell
microarray chip.
Fluorescence detection of T lymphoblastoid leukemia
and carcinoma cells in the microchambers
Scanning images of T lymphoblastoid leukemia stained with
APC-labeled anti-CD 45 monoclonal antibody on a cell
microarray chip are shown in Fig. 6A, B. All microchambers
contained fluorescence-positive cells (Fig. 6A), and high-magni-
fication images of the microchambers showed that fluorescence-
positive pixels were tightly confined (Fig. 6B). Light microscopic
Figure 6. Fluorescence detection of T lymphoblastoid leukemia and carcinoma cells in the microchambers. (A,D) Scanning images of T
lymphoblastoid leukemia (A) and carcinoma cells (D) stained with APC-labeled anti-CD 45 monoclonal antibodies in 128 microchambers. (B, E)
Magnified views of the boxed regions in ‘‘A’’ and ‘‘D,’’ respectively. (C, F) Light microscopic images of microchambers in ‘‘B’’ and ‘‘E,’’ respectively,
showing tight confinement of the cells as a monolayer. (G, J) Scanning images of leukocytes (G) and carcinoma cells (J) stained with PE-labeled anti-
cytokeratin monoclonal antibodies in 128 microchambers. (H, K) Magnified views of the boxed regions in ‘‘G’’ and ‘‘J.’’ (I, L) Light microscopic images
of microchambers in ‘‘H,’’ ‘‘K,’’ respectively, showing cells tightly confined as a monolayer. (M, P) Scanning images of leukocytes (M) and carcinoma
cells (P) stained with DiD in 128 microchambers. (N, Q) Magnified views of the boxed regions in ‘‘M’’ and ‘‘P,’’ respectively. (O, R) Light microscopic
views of microchambers in ‘‘N’’ and ‘‘Q,’’ respectively, showing tight confinement of cells as a monolayer. (Bar: 20 mm). Color scale at the right
represents the intensity of fluorescent emission.
doi:10.1371/journal.pone.0032370.g006
Figure 5. Dispersion of leukocytes isolated from whole blood on a cell microarray chip and confinement in the microchambers. (A,
B) Photographic light microscopic images of leukocytes on a cell microarray chip before (A) and after (B) washing of the chip surface. (C) The
leukocytes showed tight confinement and had formed a monolayer in the microchamber. (Bar: 20 mm).
doi:10.1371/journal.pone.0032370.g005
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monolayer (Fig. 6C). Scanning images of carcinoma cells stained
with APC-labeled anti-CD 45 monoclonal antibody on a cell
microarray chip are shown in Fig. 6D, E. No fluorescence-
positive cells were observed in the microchambers (Fig. 6D, E),
but the light microscopic view revealed the presence of a
monolayer of tightly confined carcinoma cells (Fig. 6F). By
staining of leukocytes with PE-labeled anti-cytokeratin monoclo-
nal antibody, no fluorescence-positive ones were observed in the
microchambers (Fig. 6G, H), though tightly confined monolayers
were seen by light microscopy (Fig. 6I). Fluorescence-positive
carcinoma cells were observed by staining with the PE-labeled
anti-cytokeratin monoclonal antibody in the microchambers
(Fig. 6J, K), with tight monolayers confirmed by light microscopy
(Fig. 6L). There was variation in the staining intensity of the
carcinoma cells, and the fluorescence intensity of the light blue
pixels (Fig. 6K) was over 10 times higher than that of those in the
case of leukocytes (Fig. 6H). By staining with the anti-CD45 or
anti-cytokeratin antibody and scanning with the microarray
scanner, the fluorescence intensity of the stained cells was 10
times higher than that of the non-stained cells. These results
indicate the validity of using the fluorescence- labeled anti-CD45
and anti-cytokeratin antibodies for the discrimination of the
carcinoma cells among the leukocytes in the microchambers. By
DiD staining, all microchambers were shown to be occupied by
leukocytes (Fig. 6M, N) or carcinoma cells (Fig. 6P, Q,
respectively), and tight monolayers were also confirmed by light
microscopy (Fig. 6O, R, respectively).
Detection of carcinoma cells in leukocyte cell
suspensions on a cell microarray chip
Fluorescent cytokeratin-positive carcinoma cells were observed
among T lymphoblastoid leukemia in the microchambers with a
cell mixture having 0.01%, 0.001%, and 0.0001% spiked
carcinoma cells (Fig. 7B–I), the total numbers of fluorescence-
positive carcinoma cells from independent experiments being
99.362.6, 9.760.3, and 1.060.0 (n=3), respectively, in the whole
microchamber area, as determined with DNASIS Array software.
The percentage of carcinoma cells was determined from the
following formula: [(number of fluorescence-positive cells/
1,000,000 leukocytes)6100]. High-magnification images of micro-
chambers containing fluorescence-positive carcinoma cells were
obtained (Fig. 7C, F, I). The percentages of epithelial carcinoma
cells in the mixture were calculated to be 0.0099360.00026%,
0.0009760.00003%, and 0.000160.0%, respectively. These
calculated mixture levels were well consistent with the levels
obtained practically. A good correlation between the calculated
percentages and expectations was observed according to simple
regression analysis (R
2=1.0).
Fluorescence-positive cells among the leukocytes isolated from
whole blood that had been spiked with the cancer cells were
detected with PE-labeled anti-cytokeratin monoclonal antibody
(Fig. 8). The rate for spiked carcinoma cells in whole blood was
determined by using the following formula: [(50 cells or 500 cells/
calculated leukocytes)6100] (Table 1). Each spike rate estimated
with the cell microarray chip was determined from the following
formula: [(number of fluorescence-positive carcinoma cells/total
Figure 7. Detection of carcinoma cells among cultured T lymphoblastoid leukemia on a cell microarray chip. (A–I) Scanned images of
leukocytes/carcinoma cells on a cell microarray chip obtained with the microarray scanner. (A) Negative control (no carcinoma cells). (B, D, G)
Carcinoma cells (0.01, 0.001, and 0.0001%) were scanned in 3, 9, and 64 clusters, respectively, on the cell microarray chip. (C, E, F, H, I) Magnified views
of the boxed regions. Color scale represents the intensity of fluorescent emission.
doi:10.1371/journal.pone.0032370.g007
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area)6100]. The estimated spike rates were well consistent with
the ones obtained practically. A good correlation between the 2
results was observed according to simple linear regression analysis
(R
2=0.9994).
Double staining of carcinoma cells on a cell microarray
chip
For verification of carcinoma cells in the microchambers,
double staining with 2 monoclonal antibodies specific for
carcinoma cells was performed (Fig. 9). Fluorescent images of
carcinoma cells among cultured T lymphoblastoid leukemia cells
stained with PE-labeled anti-cytokeratin monoclonal antibody
(Fig. 9A) or APC-labeled anti-EpCAM monoclonal antibody
(Fig. 9C) were obtained, and the merged image identified the
doubly positive carcinoma cells (Fig. 9E). Likewise, the same
results were obtained for the whole blood spiked with carcinoma
cells (Fig. 9G, I, K, respectively). Scatter plots demonstrated that
the cytokeratin-positive cells were also EpCAM positive (Fig. 9M).
Several times higher fluorescence intensity was observed than that
of leukocytes with either staining. These results indicate the
usefulness of the cell microarray chip and staining with 2
antibodies specific for verification of carcinoma cells among
cultured T lymphoblastoid leukemia and/or leukocytes isolated
from whole blood.
Discussion
For the sensitive detection of CTCs in peripheral blood, an
enrichment process is frequently employed, e.g., filtration, density
gradient or immunomagnetic [2]. In the filtration and density
gradient methods, there are the disadvantages of low sensitivity
and/or low specificity. The CellSearch
TM system, which is an
FDA-approved CTC diagnosis system on the market, employs an
automated and immunomagnetic method for quantification of
CTCs. It uses ferrofluid nanoparticles coated with anti-EpCAM
antibodies to isolate and enrich for CTCs that express the EpCAM
molecule on their cell surface; and anti-cytokeratin antibodies are
used to identify CTCs. So, the simultaneous expression of EpCAM
and cytokeratin on the same CTCs is the key factor for accurate
detection of CTCs. Several prospective studies using patients with
metastatic breast, colorectal or prostate cancer have shown that
above a cut-off value of 5 CTCs per 7.5 ml of blood have poor
survival prospects [9]; and changes in CTC counts during systemic
therapy can serve as an early marker for a positive or negative
response to treatment [10]. Variation in the molecular character-
istics of CTCs is well known [9]. For example, there are 5 subtypes
of human breast cancers based on global gene expression profiling,
i.e., normal-like, basal, HER2-positive, and luminal A and B [11].
Normal-like cells lack EpCAM expression, and these cells are thus
missed when CTCs are captured by an EpCAM-based method
such as the CellSearch System
TM [10,11].
The unique microfluidic platform named ‘‘CTC-chip’’ consist-
ing of an array of 78,000 microspots coated with anti-EpCAM
antibodies was reported to isolate CTCs [3]. EpCAM-positive cells
are captured on the microspots when whole blood is passed
through the microfluidic device, and these cells are detected by
analysis of the expression of tumor markers [2,3]. Capture
efficiency is dependent on the level of EpCAM expression, and
the limitation is that the CTC-chip is suitable only for EpCAM-
positive cells [2,12]. The most common epithelial markers are
cytokeratins, which are cytoskeletal proteins expressed in epithelial
cells; and EpCAM, a cell-adhesion molecule is present on
epithelial cells as well [2]. Cytokeratins are specific markers of
epithelial cells and can be used as one criterion for carcinoma
detection [13]. As was shown in Figs. 7 and 8, the use of
fluorescence-labeled anti-cytokeratin antibody for the detection of
carcinoma cells among cultured T lymphoblastoid leukemia or
Table 1. Analysis of spiked carcinoma cells in human whole blood on a cell microarray chip.
Sample* number of Leukocytes spike rate number of cells** number of leukocytes number of carcinoma cells estimated spiked rate
(/10 ml) (%) (/microchamber) (/chip) (/chip) (%)
1 25,600,000 0.000195 8963.1 1,860,000 4 0.000215
2 26,200,000 0.000191 9062.7 1,880,000 4 0.000213
3 16,800,000 0.000298 8762.2 1,820,000 5 0.000275
4 27,800,000 0.000180 8964.2 1,860,000 3 0.000161
5 25,400,000 0.00197 8965.2 1,860,000 38 0.00204
6 26,200,000 0.00191 8762.3 1,820,000 37 0.00203
7 27,600,000 0.00181 8963.7 1,860,000 34 0.00183
*Samples no. 1 to 4 were spiked with 50 carcinoma cells; and 5 to 7, were spiked with 500 carcinoma cells,
**Ten microchambers were randomly selected on a cell microarray chip, and the number of carcinoma cells in each of the chambers was counted.
doi:10.1371/journal.pone.0032370.t001
Figure 8. Detection of carcinoma cells among leukocytes/
carcinoma cells isolated from whole blood and introduced
onto a cell microarray chip. (A) Scanned images of cells on a cell
microarray chip, obtained with the microarray scanner. The cells were
immunostained with PE-labeled anti-cytokeratin monoclonal antibody.
(B) Magnified view of the boxed region. Color scale represents the
intensity of fluorescent emission.
doi:10.1371/journal.pone.0032370.g008
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accurate detection of CTCs was obtained because only fluores-
cence-labeled anti-cytokeratin antibody-binding cells among
mono-layered leukocytes were targeted and detected with the
confocal fluorescence laser scanning system. The importance of
analyzing the expression of cell-surface antigens and/or gene
expression for the distinct prognostic and therapeutic character-
istics for cancer is well known [12,14–16]. As was shown in Fig. 9,
this cell microarray technology is quite suitable for the analysis of
protein expression on cell membranes by staining with multi-
antibodies for the characterization of carcinoma cells; and the
staining procedure is easy because the fluorescence-labeled
antibody solution is simply dispersed onto the cell microarray
chip and the chip washed prior to scanning. Previously we
reported the recovery of single cells by using a micromanipulator
and a cell microarray chip having microchambers with a diameter
of 10 mm, with gene analysis performed by PCR for the cell
characterization [7]. Although we did not recover the carcinoma
cells from the microchambers in the present study, for gene
analysis by PCR it would be easy to recover them by using a
micromanipulator; because the present cell microarray chip has
microchambers with a diameter of 105 mm.
Interestingly, 3 times more leukocytes could be accommodated
in the microchambers on the cell microarray chip with cells
isolated from whole blood (Fig. 5) than with cultured T
lymphoblastoid leukemia, CCRF-CEM (Fig. 3). This observation
must have been due to the smaller cell diameter of the former.
CTCs are very rare, with an expected concentration as low as 1
cell per 10
5–10
7 mononuclear cells [2]. The CellSearch System
can detect 1 CTC in 7.5 ml of whole blood [17], meaning that a
maximum of 1610
8 leukocytes can be analyzed with this system.
As just 1.8610
6 leukocytes isolated from whole blood can be
analyzed on a single cell microarray chip, over 50 chips would be
needed to analyze statistically the numbers of leukocytes.
Obviously, this would not be realistic in clinical use. So, we need
to increase the number of microchambers on a cell microarray
chip and/or improve the design of the microchambers to
accommodate a larger number of leukocytes. Although our
present cell microarray chip technology is insufficient in ability
for analyzing large cell numbers, we have shown the potential of
the cell microarray chip for accurate detection of CTCs by
determining protein expression on cancer cell membranes by
multi-antibody staining.
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